$2.43
▼ -2.8% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Wins US FDA Orphan Drug Status for IKT-001 in Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Overview
52-week range
$1.33
$2.61
86% of range
Avg surprise (last 3)
-19.5%
Avg reaction (last 2)
-5.2%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.11 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.10 | $-0.10 | 0.0% | +33.3% | -5.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.13 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.11 | $-0.09 | -22.2% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.15 | $-0.11 | -36.4% | — | -4.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.65 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.66 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.73 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.86 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.11 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.98 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | $0 | $0 | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-21M | $-18M | — | $-13M | $-11M | $-15M | — | $-6M |
| Net income | $-20M | $-16M | — | $-12M | $-10M | $-14M | — | $-6M |
| EPS (diluted) | $-0.11 | $-0.10 | — | $-0.13 | $-0.11 | $-0.15 | — | $-0.65 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $31M | $50M | $139M | $38M | $78M | $73M | — | $913,420 |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $162M | $172M | $180M | $79M | $89M | $94M | $98M | $4M |
| Total assets | $164M | $173M | $181M | $80M | $89M | $94M | $99M | $4M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $10M | $6M | $8M | $7M | $9M | $9M | $4M | $5M |
| Total equity | $153M | $168M | $173M | $73M | $80M | $86M | $95M | $-530,591 |
Implied volatility — last 90 days
No IV snapshots yet for IKT.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.